PPARG and arthritic joint disease: Arthritis severity was reduced from day 14 by both PPAR-γ agonists, reaching an improvement of 23% for 10 mg/kg/day of rosiglitazone and 49% for 30 mg/kg/day of pioglitazone on day 21 (Figure 3a).